|
|
3344 N. Torrey Pines Court, Suite 200
La Jolla, CA 92037 USA
phone:(858) 875-8600
fax:(858) 875-8650
|
|
| Symbol |
OREX |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.orexigen.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Anti-obesity drug development. |
|
| Management |
| Michael Narachi, President And Chief Executive Officer; Graham Cooper, Chief Financial Officer; Eduardo Dunayevich, M.D., Chief Medical Officer; Mark Booth, Chief Commercial Officer; Jay Hagan, Senior Vice President, Corporate Development And Strategy |
| |
|
|
|
|
|
|
|
| Keywords |
| obesity, bupropion SR, naltrexone SR, heart disease, high blood pressure |
|
|
|
| Description |
|
Orexigen Therapeutics, Inc. is focused on developing novel therapeutics for the treatment of obesity. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
